Correction: The dual PI3K/mTOR inhibitor dactolisib elicits anti-tumor activity in vitro and in vivo

PDF  |  How to cite

Oncotarget. 2018; 9:17255-17255. https://doi.org/10.18632/oncotarget.25063

Metrics: PDF 1200 views  |   ?  

Fei Shi1,*, Jinying Zhang2,*, Hongyu Liu3, Liangliang Wu3, Hongyu Jiang4, Qiyan Wu3, Tianyi Liu3, Meiqing Lou1,# and Hao Wu5,#

1Department of Neurosurgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200000, China
2Institute of Basic Medicine Science, Chinese PLA General Hospital, Beijing 100853, China
3Key Laboratory of Cancer Center, Chinese PLA General Hospital, Beijing 100853, China
4Department of Anesthesiology, Wuxi Third People’s Hospital, Wuxi, Jiangsu 214000, China
5Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing 100053, China
*These authors contributed equally to this work
#Co-senior authors

Published: March 30, 2018

This article has been corrected: Dr. Meiqing Lou is included as a co-corresponding author.

Correspondence to: Hao Wu, email: haowu017@126.com

Correspondence to: Meiqing Lou, email: loumqdoc@126.com

Original article: Oncotarget. 2018; 9:706-717 DOI: https://doi.org/10.18632/oncotarget.23091.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 25063